Schedule I means the government treats a drug as having no medical value and high abuse risk — the harshest legal category. The DEA (which controls drug scheduling) almost never moves drugs to easier schedules on its own. Instead, it creates special exemptions letting researchers access Schedule I drugs for studies while keeping them illegal everywhere else. That's probably what will happen with psychedelics — not actual legalization, but research carve-outs.
DEA's institutional history shows no voluntary rescheduling of a substance with abuse potential absent a court order or congressional mandate. The enhanced exemption framework (expanded research access while preserving Schedule I status) is the documented institutional response to political pressure — seen with MDMA and psilocybin research exemptions. The current administration's posture toward drug enforcement further reduces rescheduling probability. Falsifiable: rescheduling of any psychedelic by 2028-01-01 would resolve FALSE. Confidence maintained at 0.77.